Amyloid goiter (AG) is a rare but well-established disease entity that may occur in a number of conditions. In the following article, we will report two cases of AG. Both patients were young males: 28 & 24 years old, presented with rapidly enlarging thyroid gland manifested with pressure effects (dyspnea and hoarseness of voice). Provisional clinical diagnosis was malignant thyroid neoplasm. One of the patients was markedly hypothyroid while the other was euthyroid. Histopathological evaluation revealed extracellular deposition of deep pink homogenous material that was confirmed as amyloid with congo red. Patient in case 1 was primary localized AG while patient in case 2 was systemic amyloidosis secondary to interstitial pulmonary fibrosis (IPF) that was first manifested by AG. The main aims of the article were to describe histopathological features of amyloidosis of the thyroid gland and to raise awareness of AG to be included in the differential diagnosis in patients presented with rapidly enlarging goiter with mass effects.
Amyloid goiter (AG) is thyroid enlargement caused by deposition of amyloid protein. Although a rare condition, AG is a well-established disease entity that was first described by Rockitansky in 1855 followed by several description of the condition in literature [
Deposition of amyloid in the thyroid gland may occur in a number of different disease conditions. It occurs in about 50% to 70% of medullary thyroid carcinoma, secondary to long standing inflammatory conditions such as rheumatoid arthritis [
Patients with AG vary in their clinical presentation and symptoms. In cases of primary AG with no significant thyroid enlargement or systemic affection, the patient is usually asymptomatic. However sometime later, many of those patients present rapidly enlarging goiter causing mass effects such as dyspnea, stridor, hoarseness of voice and dysphagia. This presentation raises high susceptibility for thyroid malignancy and therefore usually diagnosed clinically as malignant lymphomas or anaplastic carcinoma particularly in elderly patients. It was reported that majority of patients with AG did have euthyroid function however few might have hypo [
According to the degree of thyroid enlargement the WHO recommended a staging system for AG that ranges from stage 0 to III. stage 0 (no apparent goiter), stage IA (palpable goiter but not clinically apparent), Stage IB (palpable clinically apparent in fully extended neck) and stage II (apparent on resting normally-positioned neck) and stage III very large goiter that is obviously apparent [
In the following article we describe two cases of stage III AG, the first case is primary organ-isolated AG while the second case is AG secondary to interstitial pulmonary fibrosis (IPF) with possible systematic affection.
・ Each patient was examined clinically for determination of degree of goiter, and signs of other systematic affection. Patients’ consents were taken for reporting their cases.
・ Laboratory investigations were conducted (Complete blood picture count using CELL-DYN 3700, thyroid function tests using Immulit-1000, liver function tests, renal function tests using Hitachi Modular, and urine analysis was manually conducted) data were collected for each patient.
・ Each patient was subjected to imaging assessment (chest X-ray, US and CT neck, chest and abdomen).
・ After surgical removal of the thyroid gland, specimens from both patients were fixed in formalin and processed to formalin fixed paraffin-embedded blocks as used in conventional histopathology labs.
・ A representative section from each specimen was stained with hematoxyline and eosin and with Congo red stain.
・ Review of PubMed data base was done using the key word “Amyloid goiter”.
A 24 years old male patient presented to surgical oncology clinic complaining of dyspnea and respiratory distress with rapidly progressively enlarged thyroid. The patient gave a long history of generalized easy fatigability and wasting which raised possibility of GIT malignancy and patient was therefore subjected to upper and lower endoscopy, however both were free. On presentation, the clinical examination revealed bilateral diffuse enlargement of the thyroid gland associated with hoarseness of voice. Provisional clinical diagnosis was Hashimoto’s thyroiditis or thyroid malignant lymphoma.
Imaging studies using neck US showed diffuse, heterogenous thyroid swelling with bilateral enlarged cervical lymph nodes with reactive features. Abdominal sonar was free. No abnormal features in spleen, liver, adrenals, kidneys, pancreas or abdominal LNs were detected. Laboratory investigations (thyroid function test) revealed marked hypothyroidism, normal range for liver functions, normal range for renal function tests and mild increase in neutrophil on complete blood count. Detailed lab findings are summarized in
The case is not associated with immuno-proliferative, chronic diseases or any other system affection, therefore was considered primary localized amyloidosis in the thyroid gland. The patient was operated for total thyroidectomy with preservation of recurrent and superior laryngeal nerves and parathyroid glands. The operation wasdone to relief respiratory distress and to obtain tissue for pathological diagnosis. Postoperative hormonal
AG case 1 test value (normal range) | AG case 2 test value (normal range) | |
---|---|---|
Thyroid function analysis | ||
TSH | 100.1 uIU/ml (0.84 - 1.72) | 2.6 (0.4 - 6.2) ml U/L |
T3 | 0.8 ng/ml (4.5 - 12.5) | 2.1 (0.96 - 2.02 ) ng/ml |
T4 | 0.01 ng/ml (0.36 - 4.7) | 12(4.8 - 12.00 ug/dl |
Calcitonin | Not measured | 6.0 (uo to 13 pg/dl) |
Hb concentration | 10.5 g/dl (13 - 18) | 8.4 g/dl (13 - 18) |
Urine analysis | ||
Color | Clear yellow | Turbid acidic urine |
Pus cells | 1 - 2 | 15 - 18 |
Albumin | Absent | Albumin ++ |
Casts | Absent | Casts +++ |
RBC | 2 - 3 | RBC 6 - 8 |
Bile and bilirubin | Nil | Normal |
Crystals | Nil | +Ca oxalate |
Liver enzymes | ||
S.G.O.T | 12.6 mg/dl (up to 45 u.D) | 19.9 mg/dl (up to 45 u.D) |
S.G.P.T | 14.8 mg/dl (up to 40 u.D) | 25.5 mg/dl (up to 40 u.D) |
Renal functions | ||
Blood urea | 28 mg/dl (15 - 45) | 34 mg/dl (15 - 45) |
Serum ceriatinin | 0.8 (0.5 - 1.36 mag/dl) | 0.5 (0.5 - 1.36 mag/dl) |
Coagulation assay | ||
Prothrombin time | 15 seconds | 14.8 second |
Prothrombin concentration | 79% | 73% |
Adrenal function profile | Not measured | VMA 24 h urine 3.8 (0 - 13.6 mg/day) |
replacement treatment was given for the patient with ensuring follow-up for early identification of any further organ affection or development of malignancies.
28 years old male patient presented to clinic complaining of rapidly growing neck mass that resulted in shortness of breath for one month duration followed by hoarseness of voice. The patient gave a history of intermittent attacks of dry cough over the recent few years. Clinical examination revealed normal blood pressure, pulse rate and temperature. Neck examination revealed enlarged thyroid gland with retrosternal extension (without raise in the jugular venous pressure) and small cervical enlarged lymph node. Chest examination revealed bilateral basal dry crepitation with occasional rhonchi. Cardiac, abdominal, neurological clinical examinations were free.
Chest imaging: X-ray showed reticulonodular pulmonary shadows that confirmed by chest CT as interstitial pulmonary fibrosis. No enlarged hilar LNs were detected. Neck imaging: US showed bilateral nodular enlargement of both lobes of the thyroid gland and one enlarged cervical LN. Multislice computed tomography (MSCT) showed the same picture. The enlarged node showed reactive features. Abdominal US and CT revealed ectopic malrotated Rt kidney in the Rt lumbar region. Lt kidney is normal. No changes in the spleen, LNs and other organs and no asitic collection. The patient has no history of environmental exposure to agents that known to cause IPF or certain drug intake. No history or clinical/laboratory evidences for connective tissue diseases. Laboratory investigations (thyroid function test) revealed euthyroid state, Liver and renal function tests did not show abnormal findings. Urine analysis revealed albuminurea with features of presence of crystal depositions with secondary infection. Detailed lab findings are summarized in
In this report, two adult male patients in the third decade presented clinically with rapidly enlarged thyroid mass causing mass effect (stridor and dyspnea). Both conditions were provisionally diagnosed as malignant thyroid tumour after clinical examination. By reviewing the literature it was found that these symptoms are common clinical presentation in patients with AG [
Although most of the case reports indicated that AG rarely affects thyroid functions, some patients do suffer thyroid dysfunction in the form of hypo or hyperthyroidism [
reported in a case of systemic amyloidosis with amyloid deposition in the pituitary gland [
In cases associated with subacute thyroiditis and in another case it was found to be due to presence of thyroid autoantibodies [
Hisopathological diagnosis of AG is an easy task for experienced pathologists. Identification of histopatho- logical features followed by Congo red staining is the most important tool in diagnosis. However it is the accurate subclassification of amyloidosis into primary versus secondary and single organ versus systemic amyloidosis
that is relatively difficult and needs numerous investigations.
Histopathological features in both patients were nearly similar. Both specimens showed wide replacement of the thyroid tissue with the amyloid deposits. The site of deposition was perivascular and parafollicular similar to what was reported in similar reviews [
Amyloid is a pathologic proteinaceous substance, deposited extracellulary in different organs in a wide variety of diseases. The amyloid protein is composed of two components; fibrillogenic protein (accounts for 95% of the protein structure) and P component (accounts for 5% of protein structure) [
Patient in case 1 did not show any clinical or laboratory evidence for chronic inflammatory conditions or other system affection therefore was diagnosed as primary localized AG. While clinical and laboratory assessment of patient in case 2 showed presence of associated IPF and possible renal affection with amyloidosis (suggested by the presence of excessive protein casts in urine). This indicates a possible systemic secondary form of amyloidosis; however confirmation with histopathological examination of rectal and gingival biopsies and immunohistochemical identification of the deposited amyloid type was not conducted. Amyloidosis was reported previously in cases of IPF [
Both patients were underwent thyroidectomy to alleviate pressure symptoms and were both ensured for follow-up for fear of appearance of malignancies especially plasma cell tumours and lymphoma in case 1 and for fear of deterioration of renal functions in case 2. It is reported that AG may appear before or after the clinical appearance of the overt malignancy and before other system affection [
The pathogenesis of secondary systemic amyloidosis is explained by excess production by serum amyloid-associated protein (SAA) that is produced by the liver in long standing inflammatory conditions due to excess stimulation with IL-6 and IL-1. Excess SAA in itself is not enough for development of amyloidosis. Normally SAA is degraded enzymatically (by monocytes-derived enzymes) into soluble components. Only in patients with monocytes enzymatic defects, SAA undergoes incomplete degradation with subsequent abnormal folding and deposition in extracellular tissues [
The outlook of secondary (reactionary) AA amyloidosis is poor due to high mortality rate due to end-stage renal disease, infection, congestive heart failure, bowel perforation, and gastrointestinal bleeding [
Occlusions derived from presentation and discussions of both cases in this report are: a) Although rare, amyoild goiter represents a clinical entity referred to surgical clinic. Because of the unusual worrying presentation, the goiter in those patients is usually diagnosed as malignant tumour; b) Considering AG in mind, diagnosis and rapid adequate management will decrease the duration of morbidity; c) Diagnosis of AG is not just a diagnosis of the amyloid deposit in the gland, two questions must be answered in each case of AG: 1) is it primary or secondary to an underlying condition? 2) Is the thyroid gland the only affected organ? Answering both questions is essential for proper treatment. Immunohistochemical subclassification for the type of the amyloid protein (AA, Al, βA, etc.) is helpful in identification of AG type and therefore for proper treatment of the underlying cause. d) Follow-up of those patients is important because AG is sometime the first manifestation for a following systemic amyloidosis or malignancy.